Literature DB >> 29205714

Genetic variants in NTCP exon gene are associated with HBV infection status in a Chinese Han population.

Wennan Wu1,2, Yongbin Zeng1,2, Jinpiao Lin1,2, Yingying Wu1,2, Tianbin Chen1,2, Zhen Xun1,2, Qishui Ou1,2.   

Abstract

AIM: Sodium taurocholate co-transporting polypeptide (NTCP) plays an important role in the enterohepatic circulation of bile acids. Recently, NTCP was identified as a hepatitis B virus (HBV) receptor. The aim of this study is to investigate the association of NTCP polymorphisms with HBV clinical outcomes and investigate the relationship between NTCP polymorphisms and the serum bile acid level in a Chinese Han population.
METHODS: The single nucleotide polymorphisms rs2296651 and rs4646285 were genotyped in 1619 Chinese Han individuals. Improved multiple ligase detection reaction was utilized to genotype. The level of bile acids was measured by the enzymatic cycling method. Quantitative polymerase chain reaction analysis was carried out to analyze the potential function.
RESULTS: In logistic regression analysis, the frequency of rs2296651 (S267F) CT genotype was higher in HBV immune recovery and healthy control groups than in the chronic HBV infection group (P = 0.001 and P < 0.001, respectively). Patients who carried allele T showed a higher bile acid level than patients who did not carry allele T (P = 0.009). The rs4646285 AA genotype was more common in the immune recovery group than in the chronic HBV infection group (P = 0.011). No difference in serum bile acid was detected between the rs4646285 wild-type patients and mutant-type patients. Quantitative reverse transcription-polymerase chain reaction showed the NTCP mRNA levels were lower in rs4646285 variants than wild types.
CONCLUSION: NTCP gene polymorphisms may be associated with the natural course of HBV infection in a Chinese Han population. The S267F variant may be a protective factor to resist chronic hepatitis B progression which showed a higher bile acid level in Chinese Han chronic HBV infection patients. The rs4646285 variants could influence the expression of NTCP at the level of transcription, and ultimately may be associated with HBV infection immune recovery.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  bile acid; clinical outcome; hepatitis B virus; single nucleotide polymorphism; sodium taurocholate co-transporting

Year:  2018        PMID: 29205714     DOI: 10.1111/hepr.13007

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  5 in total

1.  Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection.

Authors:  Toni Herta; Magdalena Hahn; Melanie Maier; Janett Fischer; Johannes Niemeyer; Mario Hönemann; Albrecht Böhlig; Florian Gerhardt; Aaron Schindler; Jonas Schumacher; Thomas Berg; Johannes Wiegand; Florian van Bömmel
Journal:  Pathogens       Date:  2022-04-27

2.  Association of NTCP polymorphisms with clinical outcome of hepatitis B infection in Thai individuals.

Authors:  Natthaya Chuaypen; Nongnaput Tuyapala; Nutcha Pinjaroen; Sunchai Payungporn; Pisit Tangkijvanich
Journal:  BMC Med Genet       Date:  2019-05-22       Impact factor: 2.103

Review 3.  Host Genetic Determinants of Hepatitis B Virus Infection.

Authors:  Zhenhua Zhang; Changtai Wang; Zhongping Liu; Guizhou Zou; Jun Li; Mengji Lu
Journal:  Front Genet       Date:  2019-08-13       Impact factor: 4.599

4.  Toll-like receptors, long non-coding RNA NEAT1, and RIG-I expression are associated with HBeAg-positive chronic hepatitis B patients in the active phase.

Authors:  Yongbin Zeng; Wennan Wu; Ya Fu; Shanjian Chen; Tianbin Chen; Bin Yang; Qishui Ou
Journal:  J Clin Lab Anal       Date:  2019-03-29       Impact factor: 2.352

5.  The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment.

Authors:  Lina Wu; Wenxiong Xu; Xuejun Li; Ying Liu; Lu Wang; Shu Zhu; Fangji Yang; Chan Xie; Liang Peng
Journal:  Front Pharmacol       Date:  2021-02-24       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.